Meta-analysis of preclinical measures of efficacy in immune checkpoint blockade therapies and comparison to clinical efficacy estimates

Table 3 Assessment of heterogeneity in efficacy measures of preclinical ICB experiments

Modifier	Log-HRs		Log-MSRs
	AIC	R²	AIC	R²
Study	991	46	329	99
Lab	1004	39	274	78
Institute	1016	34	235	65
Strain	1050	17	31	64
Cell	1025	28	224	57
Number of tumor cells injected	1047	17	25	52
Day of treatment start after tumor inoculation	1052	15	27	51
Cancer type	1038	20	86	50
Sex	1043	15	37	48
Randomization	1055	14	31	48
Blinded assessment	1055	15	32	48
Site of injection	1057	13	47	47
Route of administration	1036	22	59	47
Dose	1050	15	33	47

ISSN: 2396-832X